益丰药房(603939) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 reached ¥5,456,496,751.25, representing a year-over-year increase of 5.31%[3] - Net profit attributable to shareholders was ¥312,782,556.35, reflecting a growth of 6.38% compared to the same period last year[3] - The net profit excluding non-recurring items was ¥306,074,278.81, with a year-over-year increase of 6.51%[3] - Basic earnings per share for the quarter were ¥0.26, an increase of 8.33% year-over-year[4] - Total operating revenue for the first three quarters of 2024 reached CNY 17,218,897,862.76, an increase from CNY 15,888,047,446.63 in the same period of 2023, representing a growth of approximately 8.36%[22] - Operating profit for the first three quarters of 2024 was CNY 1,585,544,439.53, up from CNY 1,468,816,500.30 in 2023, reflecting a growth of approximately 7.93%[22] - The total profit for Q3 2024 was approximately ¥1.58 billion, an increase from ¥1.47 billion in Q3 2023, representing a growth of about 7.6%[23] - The net profit attributable to shareholders of the parent company reached approximately ¥1.11 billion, compared to ¥999.18 million in the same period last year, marking a year-on-year increase of about 11.2%[23] - The basic and diluted earnings per share for Q3 2024 were both ¥0.92, up from ¥0.83 in Q3 2023, reflecting a growth of approximately 10.8%[24] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥27,211,502,295.78, a 12.74% increase from the end of the previous year[4] - The company's total assets as of the end of the reporting period amounted to CNY 27,211,502,295.78, compared to CNY 24,136,539,194.64 at the end of the previous year, marking an increase of about 12.83%[19] - Total liabilities increased to CNY 16,311,796,203.09 from CNY 13,689,451,532.80, representing a growth of approximately 19.06%[19] - Shareholders' equity attributable to the parent company was ¥10,253,079,010.09, up 4.58% from the previous year[4] - The company's equity attributable to shareholders reached CNY 10,253,079,010.09, compared to CNY 9,804,432,476.56 in the previous year, indicating an increase of about 4.56%[19] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥3,341,774,378.18, showing a growth of 15.96%[3] - Cash inflows from operating activities totaled approximately ¥18.85 billion, compared to ¥17.56 billion in the previous year, indicating an increase of about 7.4%[24] - The cash outflows from operating activities amounted to approximately ¥15.51 billion, up from ¥14.68 billion in the same period last year, which is an increase of about 5.6%[25] - The net cash flow from investing activities was negative at approximately -¥3.67 billion, worsening from -¥1.75 billion in the previous year[25] - The net cash flow from financing activities was also negative at approximately -¥90.66 million, compared to -¥1.54 billion in Q3 2023, showing an improvement[25] - The cash and cash equivalents at the end of Q3 2024 were approximately ¥2.05 billion, down from ¥2.51 billion at the end of Q3 2023, a decrease of about 18.1%[25] Store Expansion and Acquisitions - In the first nine months of 2024, the company added 2,254 stores, including 1,262 self-built stores, 353 acquired stores, and 639 franchise stores, resulting in a total of 15,050 stores by the end of the reporting period, a net increase of 1,800 stores[13] - The company completed two acquisition projects during the reporting period, including the acquisition of 80% of Hebei Wocheng Xinxing Ankang Pharmaceutical Chain Co., Ltd. for RMB 29.6 million, involving 49 stores, with the equity transfer completed in August 2024[13] - The company also acquired assets and businesses from 11 pharmacies for RMB 2.5 million, with the asset transfer completed in September 2024[15] Current Assets - As of September 30, 2024, the company's total current assets amounted to RMB 14,674,572,132.89, an increase from RMB 12,128,910,739.25 at the end of 2023[16] - The company's cash and cash equivalents decreased from RMB 3,565,905,738.81 at the end of 2023 to RMB 3,228,417,302.16 as of September 30, 2024[16] - The company's trading financial assets increased significantly from RMB 1,630,720,887.94 at the end of 2023 to RMB 4,829,060,856.59 as of September 30, 2024[16] - Accounts receivable decreased from RMB 2,138,274,319.88 at the end of 2023 to RMB 1,678,913,338.21 as of September 30, 2024[16] - The company's inventory increased from RMB 3,807,963,660.86 at the end of 2023 to RMB 3,897,488,801.39 as of September 30, 2024[16] - Other current assets increased from RMB 384,124,342.84 at the end of 2023 to RMB 447,070,028.11 as of September 30, 2024[16] - The company reported a significant increase in debt investment from RMB 154,167,777.78 at the end of 2023 to RMB 208,040,971.84 as of September 30, 2024[16] Research and Development - Research and development expenses for the first three quarters of 2024 were CNY 25,185,648.10, up from CNY 15,256,402.00 in 2023, reflecting a growth of approximately 64.93%[22]